![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Biotest AG | TG:BIO | Tradegate | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 41.60 | 41.60 | 42.40 | 0.00 | 14:18:06 |
RNS Number:6475U BioFocus PLC 27 January 2004 For Immediate Release 27 January 2004 BIOFOCUS GRANTS ASTRAZENECA ACCESS TO THEMATIC ANALYSIS TECHNOLOGY Chesterford Research Park, UK, 27 January 2003 - BioFocus plc (AIM: BIO), a world leader in collaborative drug discovery, today announces it has granted AstraZeneca access to its Thematic Analysis(TM) technology. BioFocus' proprietary technology enables rapid acceleration of early-stage drug discovery. This agreement allows AstraZeneca to apply Thematic Analysis(TM) to all of its G-protein coupled receptor (GPCR) targets. The proven technology will be used to design novel compounds that 'hit' GPCRs - the targets for more than 40% of the drugs currently on the market. This group of drug targets are very important as they are implicated in a broad range of diseases, including obesity, diabetes, cancer and depression. Under the terms of the agreement, BioFocus will provide AstraZeneca with access to its know-how in the area of GPCR drug design. Geoff McMillan, BioFocus' Chief Executive, said: "This new collaboration highlights the strength of our Thematic Analysis(TM) technology suite. We are very pleased that, once more, we can use this technology to help major companies such as AstraZeneca in their search for new world class drugs." For further information BioFocus +44 (0)1799 533500 Geoff McMillan, Chief Executive Buchanan Communications +44 (0)20 7466 5000 Tim Anderson/Rebecca Skye Dietrich Notes to Editors Thematic Analysis has been developed by BioFocus to enable the rational design of GPCR lead-finding libraries and rapid GPCR hit-to-lead optimisation. It is a novel, predictive and knowledge-based technology which specifically associates defined topological patterns within families of receptors to key structural features of molecules. About BioFocus BioFocus is a leading drug discovery company working in partnership with major pharmaceutical and biotechnology companies. Additionally it is developing a portfolio of internal drug discovery programmes aimed at providing drug leads for partnering. The company was founded in 1997 and is quoted on the Alternative Investment Market of the London Stock Exchange. BioFocus works with a wide range of global clients and in 2002 provided services and/or products to 22 leading pharmaceutical companies. About AstraZeneca AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the top five pharmaceutical companies in the world with healthcare sales of over $17.8 billion and leading positions in sales of gastrointestinal, oncology, cardiovascular, neuroscience and respiratory products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global and European) as well as the FTSE4Good Index. Worldwide, AstraZeneca has six major research and development sites and four discovery sites employing more than 11,000 people in six countries including Canada, France, India, Sweden, United Kingdom and the United States. For more information, please visit www.astrazeneca.com/research. This information is provided by RNS The company news service from the London Stock Exchange END AGRUNONRSBRAUAR
1 Year Biotest Chart |
1 Month Biotest Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions